JP7677995B2 - ガレクチン-3の低分子阻害剤 - Google Patents

ガレクチン-3の低分子阻害剤 Download PDF

Info

Publication number
JP7677995B2
JP7677995B2 JP2022568549A JP2022568549A JP7677995B2 JP 7677995 B2 JP7677995 B2 JP 7677995B2 JP 2022568549 A JP2022568549 A JP 2022568549A JP 2022568549 A JP2022568549 A JP 2022568549A JP 7677995 B2 JP7677995 B2 JP 7677995B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
carboxylate
give
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022568549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525527A5 (cg-RX-API-DMAC10.html
JP2023525527A (ja
Inventor
ラオ ジャラガム,プラサダ
ジェタナンド ナラ,スシール
パンダ,マノランジャン
ナテサン,ムルゲサン
デバステール,プラティク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023525527A publication Critical patent/JP2023525527A/ja
Publication of JP2023525527A5 publication Critical patent/JP2023525527A5/ja
Application granted granted Critical
Publication of JP7677995B2 publication Critical patent/JP7677995B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022568549A 2020-05-11 2021-05-10 ガレクチン-3の低分子阻害剤 Active JP7677995B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022627P 2020-05-11 2020-05-11
US63/022,627 2020-05-11
PCT/US2021/031479 WO2021231243A1 (en) 2020-05-11 2021-05-10 Small molecule inhibitors of galectin-3

Publications (3)

Publication Number Publication Date
JP2023525527A JP2023525527A (ja) 2023-06-16
JP2023525527A5 JP2023525527A5 (cg-RX-API-DMAC10.html) 2024-05-20
JP7677995B2 true JP7677995B2 (ja) 2025-05-15

Family

ID=76284161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568549A Active JP7677995B2 (ja) 2020-05-11 2021-05-10 ガレクチン-3の低分子阻害剤

Country Status (6)

Country Link
US (1) US12286424B2 (cg-RX-API-DMAC10.html)
EP (1) EP4149939A1 (cg-RX-API-DMAC10.html)
JP (1) JP7677995B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230009433A (cg-RX-API-DMAC10.html)
CN (1) CN115551850A (cg-RX-API-DMAC10.html)
WO (1) WO2021231243A1 (cg-RX-API-DMAC10.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519625A (ja) 2017-05-12 2020-07-02 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 疾患の予防および治療用の化合物およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC10.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
CA3062649A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
US12269819B2 (en) * 2019-04-10 2025-04-08 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519625A (ja) 2017-05-12 2020-07-02 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニーGalectin Sciences, LLC 疾患の予防および治療用の化合物およびその使用

Also Published As

Publication number Publication date
US20230212158A1 (en) 2023-07-06
CN115551850A (zh) 2022-12-30
KR20230009433A (ko) 2023-01-17
WO2021231243A1 (en) 2021-11-18
US12286424B2 (en) 2025-04-29
JP2023525527A (ja) 2023-06-16
EP4149939A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
CN114025844B (zh) 蛋白酪氨酸磷酸酶抑制剂及其使用方法
WO2023030385A1 (zh) 嘧啶并环类化合物及其制法和用途
CN115215838B (zh) 用于治疗特定白血病的化合物
JP2026063013A (ja) ヘテロ環glp-1アゴニスト
WO2024061370A1 (zh) 嘧啶并环类化合物及其制法和用途
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
RU2666349C2 (ru) Новое конденсированное пиримидиновое соединение или его соль
JP7577682B2 (ja) ガレクチン-3の低分子阻害剤
TW201630907A (zh) TGFβR拮抗劑
CN105541693B (zh) 芳杂环类衍生物及其在药物上的应用
JP7478165B2 (ja) ガレクチン-3の低分子阻害剤
WO2025218811A1 (zh) pan-KRAS靶向蛋白降解剂及其制备方法和应用
TW202430522A (zh) 一種用於bcl-2蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用
CN110272425B (zh) 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN114980975A (zh) 二氢环戊二烯并异喹啉磺酰胺衍生物
WO2023016521A1 (zh) 取代三唑类衍生物、其制备方法、药物组合物和用途
CN107207516B (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途
JP2023525527A (ja) ガレクチン-3の低分子阻害剤
WO2024175121A1 (zh) α,β-不饱和酰胺类化合物及其应用
CN121443603A (zh) 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物
CN110167946A (zh) 具有tnap抑制活性的磺酰胺化合物
CN115551855A (zh) 半乳凝素-3的小分子抑制剂
WO2024245193A1 (zh) 杂芳环类化合物、其药物组合物及其应用
HK40052099A (en) Compounds for treating certain leukemias
HK40052099B (en) Compounds for treating certain leukemias

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240509

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250501

R150 Certificate of patent or registration of utility model

Ref document number: 7677995

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150